Press Releases

Year

Jul 10 2017

Intec Pharma Appoints U.S. Life Sciences Executive and Vice Chairman Jeffrey A. Meckler as Chief Executive Officer

JERUSALEM, July 10, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the appointment of Jeffrey A.

May 31 2017

Intec Pharma to Participate at Upcoming June Conferences

Intec Pharma Ltd. (Nasdaq:NTEC)(TASE:NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the company will participate at the following two upcoming June conferences: LD Micro Invitational Date and

May 24 2017

Intec Pharma Granted U.S. Patent for Accordion Pill™ Comprising Levodopa for Improved Treatment of Parkinson's Diseases Symptoms

JERUSALEM, May 24, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the United States Patent and Trademark Office has granted the Company patent

May 03 2017

Intec Pharma Announces CEO Change

JERUSALEM, May 3, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that Zeev Weiss, Chief Executive Officer and a Director of the Company,

Apr 09 2017

Intec Pharma Appoints U.S. Life Sciences Executive Jeffrey A. Meckler to its Board of Directors as Vice Chairman

JERUSALEM, April 9, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced the appointment of Jeffrey A.

Apr 07 2017

Intec Pharma Reports 2016 Fourth Quarter and Full Year Financial Results

JERUSALEM, April 7, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq and TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today reported financial results for the three and 12 months ended December 31,

Mar 29 2017

Intec Pharma Provides Update on Phase III ACCORDANCE Study of the Accordion Pill Carbidopa/Levodopa in Parkinson's Disease Patients

Expects to Complete Enrollment in the Fourth Quarter of 2017 JERUSALEM, March 29, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq; TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today provided an

Mar 22 2017

Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies

JERUSALEM, March 22, 2017 /PRNewswire/ -- Expects Phase I Results in the Third Quarter of 2017 Intec Pharma Ltd. (Nasdaq; TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces the initiation of a

Mar 17 2017

Intec Pharma to Participate in the Oppenheimer 27th Annual Healthcare Conference

JERUSALEM, March 17, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that the Company will participate at the Oppenheimer 27th Annual Healthcare

Mar 10 2017

Intec Pharma to Participate in the 29th Annual Roth Conference

ntec Pharma Ltd. (Nasdaq: NTEC), a late stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, announces that Company management will participate at the 29 th Annual Roth Conference taking place from March 13-15, 2017 at the Ritz

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Page 6
Current page 7
Page 8
Page 9
Page 10
Next page
Last page

Displaying 61 - 70 of 98